NEOS Investment Management LLC Grows Position in Medtronic PLC $MDT

NEOS Investment Management LLC boosted its position in shares of Medtronic PLC (NYSE:MDT) by 35.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 168,306 shares of the medical technology company’s stock after purchasing an additional 44,197 shares during the period. NEOS Investment Management LLC’s holdings in Medtronic were worth $16,029,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in MDT. Brighton Jones LLC boosted its holdings in Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after acquiring an additional 37,265 shares during the period. Sivia Capital Partners LLC lifted its position in shares of Medtronic by 9.6% during the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after purchasing an additional 381 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Medtronic during the second quarter worth $10,286,000. Chicago Partners Investment Group LLC boosted its stake in shares of Medtronic by 17.6% during the second quarter. Chicago Partners Investment Group LLC now owns 8,194 shares of the medical technology company’s stock valued at $754,000 after purchasing an additional 1,224 shares during the period. Finally, Lyell Wealth Management LP bought a new position in shares of Medtronic in the second quarter worth about $893,000. Institutional investors own 82.06% of the company’s stock.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q3 beat — Medtronic exceeded consensus on revenue (~$9.02B) and adjusted EPS ($1.36), driven by robust demand for heart devices and diabetes monitors, supporting the bullish growth story. Medtronic beats quarterly profit estimates on robust demand for heart devices
• Positive Sentiment: Strong segment performance — Cardiovascular (including cardiac ablation/PFA) and Diabetes delivered outsized growth (cardiac ablation growth cited very strong), making this one of the company’s best quarters in recent years and underpinning revenue momentum. Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters
• Positive Sentiment: Regulatory/product wins — FDA clearance and immediate commercial activity for the Hugo™ robotic system (first U.S. case performed) and clearances for other surgical/spine systems expand addressable markets and could accelerate procedure volumes. Medtronic announces first surgery with Hugo™ robotic-assisted surgery system in the U.S. performed at Cleveland Clinic
• Positive Sentiment: Additional approvals and pipeline progress — FDA nod for Infuse bone graft in TLIF procedures and MiniMed Flex submission keep product catalysts on the calendar for surgical and diabetes franchises. Medtronic gets FDA nod for Infuse bone graft in TLIF procedures
• Neutral Sentiment: Guidance reiterated — Management reaffirmed FY26 organic revenue and EPS guidance (EPS range ~5.620–5.660), which was neither a downside shock nor a strong upside catalyst; investors are parsing precision of margins and timing of improvement. Medtronic Reaffirms 2026 Outlook As Heart and Diabetes Units Drive Growth
• Neutral Sentiment: Technicals/analyst outlook — Technical analysts and MarketBeat highlight a “textbook” reversal and institutional accumulation that imply upside targets in the $118–$125 range; this is supportive longer term but doesn’t offset near‑term margin concerns. Medtronic’s “Textbook” Reversal: How High Can It Really Go in 2026?
• Negative Sentiment: Margin pressures and costs — Investors reacted to margin contraction (tariffs, higher costs, and investments) and reports that GAAP profit fell despite higher revenue; these near‑term profitability headwinds help explain the stock decline. Medtronic Profit Falls Despite Higher Revenue

Medtronic Stock Performance

Shares of NYSE:MDT opened at $96.33 on Wednesday. The firm has a 50 day moving average of $99.19 and a 200 day moving average of $96.58. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $123.50 billion, a price-to-earnings ratio of 25.96, a price-to-earnings-growth ratio of 2.62 and a beta of 0.71. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s dividend payout ratio is presently 76.55%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on MDT shares. Wells Fargo & Company started coverage on shares of Medtronic in a report on Friday, January 30th. They set an “overweight” rating and a $114.00 price objective for the company. JPMorgan Chase & Co. raised their target price on shares of Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research report on Thursday, November 13th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Barclays initiated coverage on Medtronic in a research note on Friday, February 13th. They issued an “overweight” rating and a $116.00 price objective on the stock. Finally, Morgan Stanley lifted their target price on Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Sixteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and an average price target of $111.21.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).